← 產業報告目錄

Leukapheresis Market by Type (Filter, Membrane Separator, Centrifugal Device), Leukopak (Mobilized, Isolated PBMC), Application (Research [Cell & Gene Therapy, Transplantation], Therapeutic), Indication, End User, Region - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-02-12頁數 411報告編號 MD6538

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The leukapheresis market was estimated to be worth USD 90.6 million in 2026 and is poised to reach USD 138.7 million by 2031, growing at a CAGR of 8.9%. The leukopaks market was estimated to be worth USD 432.1 million in 2026 and is poised to reach USD 1,883.9 million by 2031, growing at a CAGR of 34.2%. This growth is driven by several key factors shaping the future of leukapheresis procedures, clinical decision-making, and advanced cell-collection workflows. The rising number of hematologic disorders and the increasing need for high-quality leukocyte collections to facilitate cell and gene therapy development and therapeutic interventions are the main factors that continue to drive growth. With the increasing use of CAR-T, TCR, NK cell therapies, and other immunotherapies, hospitals, blood centers, and apheresis units are rapidly upgrading their leukapheresis capabilities by acquiring advanced leukapheresis systems that feature automated controls, continuous, flow platforms, and GMP, compliant disposables, which help them to improve collection accuracy, maintain cell viability, and achieve timely clinical interventions. On top of that, the increasing incidence of hematologic disorders, autoimmune diseases, and immune-mediated conditions is driving up the demand for high-quality leukocyte collections. Hospitals and research centers are leaning toward advanced leukapheresis modalities, such as continuous, flow apheresis systems, membrane-based separators, and automated GMP-compliant platforms, as they are more precise, efficient, and scalable for cell collection. Also, the market expansion is being spurred by the transition toward digital apheresis workflows, which include electronic documentation, donor-monitoring systems, and integrated data platforms. This shift not only helps in procedure standardization but also enables remote monitoring and connectivity with cell therapy manufacturing records. Besides that, technological advances, including AI, assisted cell, quality assessment, predictive analytics, and cloud-based workflow management, are playing a part in the market growth. They increase the efficiency of collection, traceability, and usability, thus providing advanced leukapheresis solutions with increased practicality in diverse clinical and research settings, ranging from large hospitals to standalone apheresis centers. “The disposables segment is projected to record the fastest growth by type during the forecast period.” Globally, the disposables segment dominated the leukapheresis market in 2025, primarily due to the increasing emphasis on standardized workflows, strict sterilization practices, and robust traceability requirements in healthcare systems. These factors collectively amplified the demand for single-use consumables. Disposables are essential in cell and gene therapy–related collections, where maintaining process uniformity, preventing contamination, and ensuring accurate documentation are critical. With the rapid global expansion of CGT manufacturing, including CAR-T, TCR-T, and stem-cell programs, the need for single-use kits, tubing sets, collection bags, filters, and closed-system consumables continues to rise steadily. “The academic & research institutes segment accounted for the largest share of the leukopaks market.” By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2025, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies is driving the growth of this end-user segment. “Asia Pacific is projected to witness the highest growth during the forecast period.” During the forecast period, the Asia Pacific region is expected to record the highest growth rate in the leukapheresis market. Some of the major reasons that work toward the growth of the market are the rising cases of hematologic disorders, the increasing use of cell and gene therapy, the development of apheresis infrastructure, and the growing investment in advanced therapeutic technologies by regional as well as global players. Moreover, the region benefits from increased public awareness of novel treatment modalities, healthcare access enhancement, rapid growth of specialty hospitals and blood transfusion centers, and higher involvement in CGT-related clinical trials. Altogether, these elements will stimulate the demand for leukapheresis procedures and consumables in Asia Pacific countries. Breakdown of supply-side primary interviews: • By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%) • By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%) • By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%) Breakdown of demand-side primary interviews: • By End User: Academic & Research Institutes (45%), Pharmaceutical & Biotechnology Companies (30%), Contract Research Organizations (25%) • By Designation: Apheresis Nurses & Practitioners (47%), Hematologists/Oncologists(22%), GMP Facility Heads (15%), and Others (16%) • By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)   Research Coverage The market study covers the leukapheresis market in various segments. It aims to estimate the market size and growth potential of this market by type, application, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their products and business offerings, recent developments, and key market strategies. Reasons to Buy the Report The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger market share. Firms that acquire the report can implement one or more of the five strategies outlined below. This report provides insights into the following points: • Analysis of key drivers, restraints, opportunities, and challenges • Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the leukapheresis market • Market Development: Comprehensive information about lucrative emerging markets • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the leukapheresis market • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the leukapheresis market
目錄 Table of Contents
1 INTRODUCTION 32 1.1 STUDY OBJECTIVES 32 1.2 MARKET DEFINITION 32 1.3 STUDY SCOPE 33 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 33 1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY 34 1.3.3 YEARS CONSIDERED 35 1.4 CURRENCY CONSIDERED 35 1.5 STAKEHOLDERS 36 1.6 SUMMARY OF CHANGES 36 2 EXECUTIVE SUMMARY 38 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 38 2.2 LEUKOPAKS MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 39 2.3 LEUKAPHERESIS MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 40 2.4 DISRUPTIVE TRENDS IN LEUKAPHERESIS MARKET 41 2.5 HIGH-GROWTH SEGMENTS 42 2.6 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 43 3 PREMIUM INSIGHTS 45 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN LEUKAPHERESIS MARKET 45 3.2 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY END USER AND COUNTRY 46 3.3 GEOGRAPHIC SNAPSHOT OF LEUKAPHERSIS MARKET 47 3.4 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN LEUKOPAKS MARKET 48 3.5 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE AND COUNTRY 49 3.6 GEOGRAPHIC SNAPSHOT OF LEUKOPAKS MARKET 50 4 MARKET OVERVIEW 51 4.1 INTRODUCTION 51 4.2 MARKET DYNAMICS 51 4.2.1 DRIVERS 52 4.2.1.1 Rising utilization of leukopaks in CAR-T cell therapy development 52 4.2.1.2 Increasing incidence and clinical burden of leukemia 52 4.2.1.3 Leukopaks and leukapheresis driving advances in research & development activities 54 4.2.1.4 Leukopaks as key contributors to CAR-T cell therapy clinical trials 54 4.2.2 RESTRAINTS 55 4.2.2.1 Elevated costs of therapeutic leukapheresis and leukopak products 55 4.2.2.2 Limited donor availability and stringent screening criteria for leukapheresis 56 4.2.2.3 Shortage of skilled healthcare professionals in apheresis and cell therapy procedures 57 4.2.2.4 Complications associated with therapeutic leukapheresis 57 4.2.3 OPPORTUNITIES 58 4.2.3.1 Increasing focus on leukapheresis in pediatric patients 58 4.2.3.2 Rise in investments in CAR-T therapies in emerging economies 58 4.2.3.3 Gaps in current leukapheresis technologies 59 4.2.4 CHALLENGES 59 4.2.4.1 Infectious disease risks related to safety of blood transfusion in emerging economies 59 4.2.4.2 Donor variability and inconsistent leukopak quality 60 4.3 UNMET NEEDS & WHITE SPACES 60 4.3.1 UNMET NEEDS IN LEUKAPHERESIS MARKET 60 4.3.2 WHITE SPACE OPPORTUNITIES 61 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 63 4.4.1 INTERCONNECTED MARKETS 63 4.4.2 CROSS-SECTOR OPPORTUNITIES 63 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64 4.5.1 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS IN LEUKAPHERESIS MARKET 64 5 INDUSTRY TRENDS 65 5.1 PORTER’S FIVE FORCES ANALYSIS 65 5.1.1 THREAT OF NEW ENTRANTS 66 5.1.2 THREAT OF SUBSTITUTES 67 5.1.3 BARGAINING POWER OF SUPPLIERS 67 5.1.4 BARGAINING POWER OF BUYERS 67 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67 5.2 MACROECONOMIC OUTLOOK 68 5.2.1 INTRODUCTION 68 5.2.2 GDP TRENDS & FORECAST 68 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 69 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 69 5.3 SUPPLY CHAIN ANALYSIS 70 5.4 VALUE CHAIN ANALYSIS 71 5.5 MARKET ECOSYSTEM 73 5.5.1 LEUKAPHERESIS MARKET PROVIDERS 74 5.5.2 END USERS 75 5.5.3 REGULATORY BODIES 76 5.6 PRICING ANALYSIS (LEUKOPAKS MARKET) 76 5.6.1 AVERAGE SELLING PRICE TREND FOR NON-MOBILIZED LEUKOPAKS, BY REGION, 2023–2025 (USD) 79 5.6.2 AVERAGE SELLING PRICE TREND FOR MOBILIZED LEUKOPAKS, BY REGION, 2023–2025 (USD) 79 5.7 TRADE ANALYSIS 80 5.7.1 IMPORT DATA FOR HS CODE 901890 80 5.7.2 EXPORT DATA FOR HS CODE 901890 80 5.8 REIMBURSEMENT SCENARIO 81 5.9 KEY CONFERENCES & EVENTS (2026–2027) 82 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 83 5.11 INVESTMENT & FUNDING SCENARIO 84 5.12 CASE STUDY ANALYSIS 85 5.13 IMPACT OF 2025 US TARIFF ON LEUKAPHERESIS MARKET 87 5.13.1 INTRODUCTION 87 5.13.2 KEY TARIFF RATES 88 5.13.3 PRICE IMPACT ANALYSIS 88 5.13.4 IMPACT ON REGIONS 89 5.13.5 IMPACT ON END-USE SEGMENTS 91 5.13.5.1 Leukapheresis 91 5.13.5.2 Leukopaks 92 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVE IMPACT, PATENTS, AND INNOVATIONS 93 6.1 TECHNOLOGY ANALYSIS 93 6.1.1 KEY EMERGING TECHNOLOGIES 93 6.1.1.1 Automated & AI-enabled apheresis systems 93 6.1.1.2 Closed-loop & GMP-compliant processing systems 93 6.1.1.3 Cryopreservation & cryo-processed leukopaks technologies 94 6.1.2 COMPLEMENTARY TECHNOLOGIES 94 6.1.2.1 Cell processing & manufacturing platforms (CGT ecosystem) 94 6.1.2.2 Digital monitoring, data integration, and workflow software 95 6.1.3 ADJACENT TECHNOLOGIES 95 6.1.3.1 Regenerative medicine & stem cell technologies 95 6.2 TECHNOLOGY/PRODUCT ROADMAP 96 6.2.1 NEAR TERM (2025–2027) 96 6.2.2 MID TERM (2028–2030) 96 6.2.3 LONG TERM (2030+) 97 6.3 PATENT ANALYSIS 97 6.3.1 JURISDICTION AND TOP APPLICANT ANALYSIS 97 6.4 FUTURE APPLICATIONS 99 6.4.1 CELL & GENE THERAPY (CAR-T, TCR, NK CELLS) 99 6.4.2 DECENTRALIZED & POINT-OF-CARE CELL COLLECTION 99 6.4.3 STEM CELL TRANSPLANTATION & REGENERATIVE MEDICINE 100   6.5 IMPACT OF AI/GEN AI ON LEUKAPHERESIS MARKET 100 6.5.1 INTRODUCTION 100 6.5.2 MARKET POTENTIAL OF AI IN LEUKAPHERESIS 100 6.5.3 AI USE CASES 101 6.5.4 KEY COMPANIES IMPLEMENTING AI 102 7 SUSTAINABILITY & REGULATORY BEHAVIOR 103 7.1 REGULATORY LANDSCAPE 103 7.1.1 REGULATORY FRAMEWORK 103 7.1.1.1 North America 103 7.1.1.2 Europe 103 7.1.1.3 Asia Pacific 103 7.1.1.4 Latin America 104 7.1.1.5 Middle East & Africa 104 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 7.1.3 INDUSTRY STANDARDS 107 7.2 SUSTAINABILITY INITIATIVES 108 7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR LEUKAPHERESIS 108 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 109 7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 109 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 110 8.1 KEY STAKEHOLDERS & BUYING CRITERIA 110 8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 110 8.1.2 BUYING CRITERIA 111 8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 111 8.2.1 DECISION-MAKING PROCESS 111 8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 112 8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113 8.2.4 MARKET PROFITABILITY 114 9 LEUKAPHERESIS MARKET, BY PRODUCT TYPE 115 9.1 INTRODUCTION 116 9.2 DISPOSABLES 116 9.2.1 SINGLE-USE, PROCEDURE-DRIVEN CONSUMPTION TO BOOST SEGMENT 116 9.2.2 TUBING SETS & COLLECTION BAGS 118 9.2.2.1 Rising leukapheresis procedure volumes driving demand for tubing sets & collection bags 118 9.2.3 FILTERS & MEMBRANE CONSUMABLES 119 9.2.3.1 Growing adoption of leukocyte removal filters in inflammatory disease management 119   9.2.4 COLLECTION KITS & ACCESSORIES 121 9.2.4.1 Increasing leukapheresis and leukopak collection activities driving demand for collection kits and accessories 121 9.3 DEVICES 123 9.3.1 CENTRIFUGAL DEVICES 124 9.3.1.1 Increasing installation in hospitals to drive market 124 9.3.1.2 Global volume analysis: Centrifugal devices market (2024–2031) 126 9.3.2 MEMBRANE SEPARATORS 127 9.3.2.1 Difficulty in separating large volumes of plasma to limit market 127 10 LEUKAPHERESIS MARKET, BY APPLICATION 129 10.1 INTRODUCTION 130 10.2 RESEARCH APPLICATIONS 130 10.2.1 EXPANDING CELL & GENE THERAPY PIPELINE TO DRIVE THE SEGMENT 130 10.3 THERAPEUTIC APPLICATIONS 132 10.3.1 INCREASING ADOPTION OF LEUKAPHERESIS IN LEUKEMIA MANAGEMENT DRIVING MARKET GROWTH 132 11 LEUKAPHERESIS MARKET, BY END USER 134 11.1 INTRODUCTION 135 11.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS 135 11.2.1 RISING BLOOD DONATION AND TRANSFUSION NEEDS DRIVING LEUKAPHERESIS DEMAND 135 11.3 HOSPITALS & TRANSFUSION CENTERS 137 11.3.1 HIGH PROCEDURAL VOLUMES IN HOSPITALS TO DRIVE LEUKAPHERESIS DEMAND 137 11.4 ACADEMIC & RESEARCH INSTITUTES 139 11.4.1 INCREASING ACADEMIC–INDUSTRY COLLABORATIONS TO BOOST MARKET 139 11.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 140 11.5.1 GROWING NUMBER OF CLINICAL TRIALS TO BOOST SEGMENT 140 12 LEUKOPAKS MARKET, BY TYPE 143 12.1 INTRODUCTION 144 12.2 MOBILIZED LEUKOPAKS 146 12.2.1 INCREASING USE OF MOBILIZED LEUKOPAKS IN CLINICAL RESEARCH TO DRIVE MARKET 146 12.2.2 GLOBAL VOLUME ANALYSIS: MOBILIZED LEUKOPAKS MARKET (2024–2031) 148 12.3 NON-MOBILIZED LEUKOPAKS 148 12.3.1 ADOPTION OF NON-MOBILIZED LEUKOPAKS DRIVEN BY LOWER COST AND CELL YIELD 148 12.3.2 GLOBAL VOLUME ANALYSIS: NON-MOBILIZED LEUKOPAKS MARKET (2024–2031) 151 12.4 DISEASED LEUKOPAKS 151 12.4.1 INCREASING DEMAND FOR DISEASE-STATE LEUKOPAKS IN ADVANCED THERAPEUTIC RESEARCH DRIVING MARKET GROWTH” 151 12.4.2 GLOBAL VOLUME ANALYSIS: DISEASED LEUKOPAKS MARKET (2024–2031) 153 12.5 ISOLATED PBMCS 153 12.5.1 INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET 153 12.5.2 GLOBAL VOLUME ANALYSIS: ISOLATED PBMCS MARKET (2024–2031) 156 13 LEUKOPAKS MARKET, BY INDICATION 157 13.1 INTRODUCTION 158 13.2 ACUTE LYMPHOCYTIC LEUKEMIA 159 13.2.1 INCREASING INCIDENCE OF ACUTE LYMPHOCYTIC LEUKEMIA SUPPORTING MARKET GROWTH 159 13.3 MULTIPLE MYELOMA 161 13.3.1 RISING MULTIPLE MYELOMA CASES DRIVING MARKET EXPANSION 161 13.4 NON-HODGKIN’S LYMPHOMA 162 13.4.1 DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET 162 13.5 CHRONIC LYMPHOCYTIC LEUKEMIA 164 13.5.1 GROWING PREVALENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA DRIVING SEGMENT EXPANSION 164 13.6 PANCREATIC CANCER 165 13.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT 165 13.7 HEPATOCELLULAR CARCINOMA 167 13.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT 167 13.8 OTHER INDICATIONS 168 14 LEUKOPAKS MARKET, BY END USER 170 14.1 INTRODUCTION 171 14.2 ACADEMIC & RESEARCH INSTITUTES 172 14.2.1 INCREASING INDUSTRY–ACADEMIC COLLABORATIONS DRIVING MARKET GROWTH 172 14.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 173 14.3.1 RISING DEMAND FOR TARGETED CELL-BASED DRUG DEVELOPMENT DRIVING LEUKOPAK ADOPTION 173 14.4 CONTRACT RESEARCH ORGANIZATIONS 174 14.4.1 INCREASING CRO-LED CLINICAL ACTIVITIES DRIVING DEMAND FOR LEUKAPHERESIS-DERIVED MATERIALS 174 15 LEUKAPHERESIS MARKET, BY REGION 177 15.1 INTRODUCTION 178 15.2 NORTH AMERICA 179 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 180 15.2.2 NORTH AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 184 15.2.3 US 184 15.2.3.1 Strong Presence of Biopharmaceutical Leaders and Expanding Cell Therapy Ecosystem Driving Market Growth 184 15.2.4 CANADA 188 15.2.4.1 Increasing Leukemia Incidence and Advancements in CAR-T Therapies Supporting Market Growth in Canada 188 15.3 EUROPE 191 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 192 15.3.2 EUROPE VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 196 15.3.3 GERMANY 196 15.3.3.1 Rising Healthcare Expenditure, Expanding Academic–Clinical Cell Therapy Ecosystem to drive market growth 196 15.3.4 UK 199 15.3.4.1 Expanding Apheresis Capacity and CAR-T Therapies Adoption to support market growth 199 15.3.1 FRANCE 202 15.3.1.1 Centralized CAR-T Delivery System and Strong Public Reimbursement to propel market growth 202 15.3.2 ITALY 205 15.3.2.1 Rising elderly patient pool and high cancer incidence to drive market growth 205 15.3.3 SPAIN 208 15.3.3.1 Rising Hematologic Cancer Burden to support market growth 208 15.3.4 BELGIUM 209 15.3.4.1 Strong Clinical Research Ecosystem and Structured Reimbursement Framework to boost the market 209 15.3.5 NETHERLANDS 209 15.3.5.1 Strong healthcare infrastructure and aging population to drive market 209 15.3.6 POLAND 212 15.3.6.1 Rise in cancer incidence to boost the market 212 15.3.7 SWITZERLAND 214 15.3.7.1 Early adoption of cell therapies to drive market demand 214 15.3.8 REST OF EUROPE 217 15.4 ASIA PACIFIC 220 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 221 15.4.2 ASIA PACIFIC VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 226 15.4.3 CHINA 227 15.4.3.1 Increasing hematologic cancer burden, CAR-T expansion, and biotech investments driving leukapheresis growth in China 227 15.4.4 JAPAN 230 15.4.4.1 Moderate-to-high healthcare expenditure supporting leukapheresis market growth 230 15.4.5 INDIA 234 15.4.5.1 Rising government investment in healthcare to drive market growth 234 15.4.6 AUSTRALIA 237 15.4.6.1 Clinical integration of CAR-T therapies in hospitals as core growth driver for leukapheresis in Australia 237 15.4.7 SOUTH KOREA 241 15.4.7.1 Integration of digital and automated cell processing technologies driving growth in the leukapheresis market 241 15.4.8 NEW ZEALAND 245 15.4.8.1 Strengthening therapeutic apheresis infrastructure as a core growth driver for the New Zealand leukapheresis market 245 15.4.9 THAILAND 248 15.4.9.1 Rising oncology demand for cell-based therapies driving leukapheresis market growth 248 15.4.10 REST OF ASIA PACIFIC 251 15.5 LATIN AMERICA 254 15.5.1 LATIN AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 258 15.5.2 BRAZIL 258 15.5.2.1 Role of blood donation, transplant activity, and cell therapy expansion in driving the leukapheresis and leukopak market 258 15.5.3 MEXICO 261 15.5.3.1 Emerging CAR-T therapy and cost-driven leukemia care market in Mexico 261 15.5.4 REST OF LATIN AMERICA 264 15.6 MIDDLE EAST & AFRICA 267 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 268 15.6.2 MIDDLE EAST & AFRICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 272 15.6.3 GCC COUNTRIES 272 15.6.3.1 Kingdom of Saudi Arabia (KSA) 272 15.6.3.1.1 Transforming clinical research in Saudi Arabia through healthcare innovation initiatives 272 15.6.3.2 United Arab Emirates (UAE) 275 15.6.3.2.1 Emergence as a Regional Hub for Advanced Precision Medicine 275 15.6.3.3 Other GCC countries 278 15.6.4 REST OF MIDDLE EAST & AFRICA 281 16 COMPETITIVE LANDSCAPE 285 16.1 INTRODUCTION 285 16.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2022–2026 285 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKAPHERESIS MARKET 286 16.3 REVENUE ANALYSIS, 2023–2025 288 16.3.1 LEUKAPHERESIS MARKET: REVENUE ANALYSIS 288 16.3.2 LEUKOPAKS MARKET: REVENUE ANALYSIS 289 16.4 MARKET SHARE ANALYSIS, 2025 290 16.4.1 LEUKAPHERESIS MARKET: SHARE ANALYSIS 290 16.4.2 LEUKOPAKS MARKET: SHARE ANALYSIS 291   16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 292 16.5.1 LEUKOPAKS MARKET 292 16.5.1.1 Stars 292 16.5.1.2 Emerging leaders 292 16.5.1.3 Pervasive players 292 16.5.1.4 Participants 292 16.5.1.5 Company footprint: Key players, 2025 294 16.5.1.5.1 Company footprint 294 16.5.1.5.2 By Region footprint 294 16.5.1.5.3 By product type footprint 295 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 295 16.6.1 LEUKOPAKS MARKET 295 16.6.1.1 Progressive companies 295 16.6.1.2 Responsive companies 295 16.6.1.3 Dynamic companies 295 16.6.1.4 Starting blocks 296 16.6.1.5 Competitive benchmarking: Startups/SMEs, 2025 297 16.6.1.5.1 Detailed list of key startups/SMEs 297 16.6.1.5.2 Competitive benchmarking of key startups/SMEs 298 16.7 COMPANY VALUATION AND FINANCIAL METRICS 298 16.7.1 FINANCIAL METRICS: LEUKAPHERESIS MARKET 298 16.7.2 COMPANY VALUATION : LEUKAPHERESIS MARKET 299 16.7.3 FINANCIAL METRICS: LEUKOPAKS MARKET 299 16.7.4 COMPANY VALUATION: LEUKOPAKS MARKET 300 16.8 LEUKOPAKS BRAND/PRODUCT COMPARISON 301 16.9 LEUKAPHEREIS BRAND/PRODUCT COMPARISON 302 16.10 COMPETITIVE SCENARIO 303 16.10.1 LEUKAPHERESIS MARKET 303 16.10.1.1 Product launches & approvals 303 16.10.1.2 Deals 304 16.10.1.3 Expansions 305 16.10.2 LEUKOPAKS MARKET 305 16.10.2.1 Product launches & approvals 305 16.10.2.2 Deals 307 16.10.2.3 Expansions 309 17 COMPANY PROFILES 311 17.1 LEUKAPHERESIS PRODUCTS MARKET: KEY PLAYERS 311 17.1.1 TERUMO CORPORATION 311 17.1.1.1 Business overview 311 17.1.1.2 Products offered 312 17.1.1.3 Recent developments 314 17.1.1.3.1 Product launches & approvals 314 17.1.1.3.2 Deals 314 17.1.1.3.3 Expansions 315 17.1.1.4 MnM view 315 17.1.1.4.1 Right to win 315 17.1.1.4.2 Strategic choices 316 17.1.1.4.3 Weaknesses & competitive threats 316 17.1.2 FRESENIUS SE & CO. KGAA 317 17.1.2.1 Business overview 317 17.1.2.2 Products offered 318 17.1.2.3 Recent developments 319 17.1.2.3.1 Product launches & approvals 319 17.1.2.3.2 Deals 320 17.1.2.3.3 Other developments 320 17.1.2.4 MnM view 320 17.1.2.4.1 Right to win 320 17.1.2.4.2 Strategic choices 320 17.1.2.4.3 Weaknesses & competitive threats 321 17.1.3 HAEMONETICS CORPORATION 322 17.1.3.1 Business overview 322 17.1.3.2 Products offered 323 17.1.3.3 Recent developments 326 17.1.3.3.1 Product launches & approvals 326 17.1.3.3.2 Deals 326 17.1.3.4 MnM view 326 17.1.3.4.1 Right to win 326 17.1.3.4.2 Strategic choices 326 17.1.3.4.3 Weaknesses & competitive threats 327 17.1.4 NIKKISO CO., LTD. 328 17.1.4.1 Business overview 328 17.1.4.2 Products offered 329 17.1.4.3 Recent developments 330 17.1.4.3.1 Other developments 330 17.1.4.4 MnM view 330 17.1.4.4.1 Right to win 330 17.1.4.4.2 Strategic choices 330 17.1.4.4.3 Weaknesses & competitive threats 330 17.1.5 SUMITOMO BAKELITE CO., LTD. 331 17.1.5.1 Business overview 331 17.1.5.2 Products offered 332 17.1.5.3 MnM view 333 17.1.5.3.1 Right to win 333 17.1.5.3.2 Strategic choices 333 17.1.5.3.3 Weaknesses & competitive threats 333 17.1.6 DANAHER CORPORATION 334 17.1.6.1 Business overview 334 17.1.6.2 Products offered 335 17.1.7 OTSUKA HOLDINGS CO., LTD. 336 17.1.7.1 Business overview 336 17.1.7.2 Products offered 337 17.1.8 ASAHI KASEI MEDICAL CO., LTD. 338 17.1.8.1 Business overview 338 17.1.8.2 Products offered 338 17.1.8.3 Recent developments 339 17.1.8.3.1 Other developments 339 17.1.9 MACOPHARMA SA 340 17.1.9.1 Business overview 340 17.1.9.2 Products offered 340 17.1.10 MEDICA SPA 342 17.1.10.1 Business overview 342 17.1.10.2 Products offered 342 17.2 LEUKAPHERESIS PRODUCTS MARKET: OTHER PLAYERS 343 17.2.1 POLYMED 343 17.2.2 PURIBLOOD MEDICAL 344 17.2.3 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO., LTD. 345 17.2.4 SAFETRAN BIOMEDICAL INC. 346 17.2.5 MITRA INDUSTRIES PRIVATE LIMITED 347 17.3 LEUKOPAKS MARKET: KEY PLAYERS 348 17.3.1 LONZA 348 17.3.1.1 Business overview 348 17.3.1.2 Products offered 349 17.3.1.3 Recent developments 351 17.3.1.3.1 Deals 351 17.3.1.4 MnM view 351 17.3.1.4.1 Right to win 351 17.3.1.4.2 Strategic choices 351 17.3.1.4.3 Weaknesses and competitive threats 351 17.3.2 GRIFOLS 352 17.3.2.1 Business overview 352 17.3.2.2 Products offered 353 17.3.3 CHARLES RIVER LABORATORIES 355 17.3.3.1 Business overview 355 17.3.3.2 Products offered 356 17.3.3.3 Recent developments 358 17.3.3.3.1 Product launches & approvals 358 17.3.3.3.2 Deals 358 17.3.3.3.3 Expansions 359 17.3.4 CELLEX CELL PROFESSIONALS 360 17.3.4.1 Business overview 360 17.3.4.2 Products offered 361 17.3.4.3 Recent developments 361 17.3.4.3.1 Deals 361 17.3.4.3.2 Expansions 362 17.3.5 STEMCELL TECHNOLOGIES 363 17.3.5.1 Business overview 363 17.3.5.2 Products offered 363 17.3.6 BIOIVT 365 17.3.6.1 Business overview 365 17.3.6.2 Products offered 365 17.3.6.3 Recent developments 367 17.3.6.3.1 Product launches & approvals 367 17.3.6.3.2 Deals 367 17.3.6.3.3 Expansions 367 17.3.7 DISCOVERY LIFE SCIENCES 368 17.3.7.1 Business overview 368 17.3.7.2 Products offered 368 17.3.7.3 Recent developments 370 17.3.7.3.1 Product launches & approvals 370 17.3.7.3.2 Deals 370 17.3.7.3.3 Expansions 370 17.3.8 MILTENYI BIOTEC 371 17.3.8.1 Business overview 371 17.3.8.2 Products offered 372 17.3.9 STEMVIVO INC. 373 17.3.9.1 Business overview 373 17.3.9.2 Products offered 374 17.3.10 CGT GLOBAL 375 17.3.10.1 Business overview 375 17.3.10.2 Products offered 375 17.3.10.3 Recent developments 377 17.3.10.3.1 Product launches & approvals 377 17.3.11 SANGUINE BIOSCIENCES 378 17.3.11.1 Business overview 378 17.3.11.2 Products offered 378 17.3.11.3 Recent developments 379 17.3.11.3.1 Product launches & approvals 379 17.4 LEUKOPAKS MARKET: OTHER PLAYERS 380 17.4.1 BIOMEX GMBH 380 17.4.2 ACCEGEN 381 17.4.3 EXCELLOS 382 17.4.4 FIRST CHOICE BIO INC. 383 17.4.5 ORGANA BIO 384 17.4.6 HUMAN CELLS BIO 384 18 RESEARCH METHODOLOGY 386 18.1 RESEARCH DATA 386 18.1.1 SECONDARY DATA 387 18.1.1.1 Key data from secondary sources 388 18.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET 391 18.3 MARKET GROWTH RATE PROJECTIONS 394 18.4 DATA TRIANGULATION 396 18.5 RESEARCH ASSUMPTIONS 397 18.5.1 GROWTH RATE ASSUMPTIONS 398 18.6 RISK ASSESSMENT 398 18.7 LIMITATIONS 399 18.7.1 METHODOLOGY-RELATED LIMITATIONS 399 18.7.2 SCOPE-RELATED LIMITATIONS 399 18.8 RESEARCH LIMITATIONS 399 18.9 RISK ANALYSIS 400 19 APPENDIX 401 19.1 DISCUSSION GUIDE 401 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 406 19.3 CUSTOMIZATION OPTIONS 408 19.3.1 COMPANY INFORMATION 408 19.3.2 GEOGRAPHIC ANALYSIS 408 19.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 408 19.3.4 COUNTRY-LEVEL VOLUME ANALYSIS 408 19.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 408 19.4 RELATED REPORTS 409 19.5 AUTHOR DETAILS 410
圖表清單 List of Tables & Figures
TABLE 1 LEUKAPHERESIS MARKET: INCLUSIONS & EXCLUSIONS 34 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35 TABLE 3 COST OF LEUKOPAKS, BY TYPE 55 TABLE 4 DONOR SELECTION CRITERIA 56 TABLE 5 FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS 57 TABLE 6 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 65 TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 68 TABLE 8 LIST OF KEY LEUKAPHERESIS DEVICES + DISPOSABLES MANUFACTURERS 74 TABLE 9 LIST OF KEY LEUKOPAKS MANUFACTURERS 75 TABLE 10 LIST OF KEY END USERS 75 TABLE 11 LIST OF KEY REGULATORY BODIES 76 TABLE 12 AVERAGE SELLING PRICE OF NON-MOBILIZED LEUKOPAKS, 2025 (USD) 77 TABLE 13 AVERAGE SELLING PRICE OF MOBILIZED LEUKOPAKS, 2025 (USD) 77 TABLE 14 AVERAGE SELLING PRICE OF DISEASED LEUKOPAKS, 2025 (USD) 78 TABLE 15 AVERAGE SELLING PRICE OF ISOLATED PBMCS, 2025 (USD) 78 TABLE 16 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 80 TABLE 17 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 80 TABLE 18 LEUKAPHERESIS MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 82 TABLE 19 CASE STUDY 1: RAPID CYTOREDUCTION IN PEDIATRIC ACUTE LEUKEMIA USING LEUKAPHERESIS 85 TABLE 20 CASE STUDY 2: GLOBAL CELL THERAPY TRIAL ENABLED BY LEUKAPHERESIS INTEGRATION 86 TABLE 21 CASE STUDY 3: THERAPEUTIC LEUKAPHERESIS IN SEVERE PNEUMONIA WITH HYPERLEUKOCYTOSIS 86 TABLE 22 US-ADJUSTED RECIPROCAL TARIFF RATES, 2024 88 TABLE 23 KEY PRODUCT-RELATED TARIFF EFFECTIVE 88 TABLE 24 NORTH AMERICA: IMPACT OF US TARIFFS 89 TABLE 25 ASIA PACIFIC: IMPACT OF US TARIFFS 89 TABLE 26 EUROPE: IMPACT OF US TARIFFS 90 TABLE 27 LATIN AMERICA: IMPACT OF US TARIFFS 91 TABLE 28 LEUKAPHERESIS MARKET: KEY PATENTS, 2023–2025 98 TABLE 29 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 30 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 31 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 32 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 TABLE 33 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 TABLE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LEUKOPAKS 110 TABLE 35 KEY BUYING CRITERIA FOR LEUKOPAKS, BY TYPE 111 TABLE 36 LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 116 TABLE 37 DISPOSABLES: LEUKAPHERESIS MARKET, BY PRODUCT TYPE 2024–2031 (USD MILLION) 117 TABLE 38 LEUKAPHERESIS DISPOSABLE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 39 TUBING SETS & COLLECTION BAGS MARKET, BY TYPE, 2024–2031 (USD MILLION) 118 TABLE 40 COMMERCIALLY AVAILABLE FILTERS & MEMBRANE CONSUMABLES 120 TABLE 41 FILTERS & MEMBRANE CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 120 TABLE 42 COMMERCIALLY AVAILABLE COLLECTION KITS & ACCESSORIES 121 TABLE 43 COLLECTION KITS & ACCESSORIES MARKET, BY TYPE,2024–2031 (USD MILLION) 122 TABLE 44 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 123 TABLE 45 CENTRIFUGAL DEVICES AVAILABLE 125 TABLE 46 CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 47 CENTRIFUGAL DEVICES VOLUME MARKET, 2024–2031 (UNITS SOLD) 126 TABLE 48 MEMBRANE SEPARATORS AVAILABLE 127 TABLE 49 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 50 LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 130 TABLE 51 COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES 131 TABLE 52 LEUKAPHERESIS MARKET IN RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 53 LEUKAPHERESIS MARKET IN THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 54 LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 135 TABLE 55 LEUKAPHERESIS MARKET FOR BLOOD COMPONENT PROVIDERS & BLOOD CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 56 LEUKAPHERESIS MARKET FOR HOSPITALS & TRANSFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 57 LEUKAPHERESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 58 CAR-T CELL THERAPY UNDER CLINICAL TRIALS 141 TABLE 59 LEUKAPHERESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 60 LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 144 TABLE 61 LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 62 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 63 MOBILIZED LEUKOPAKS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS) 148 TABLE 64 NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS 148 TABLE 65 COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS 149 TABLE 66 COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS 149 TABLE 67 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 68 NON-MOBILIZED LEUKOPAKS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS) 151 TABLE 69 DISEASED CELL LEUKOPAKS AND THEIR ROLE IN CELL THERAPY 152 TABLE 70 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 71 DISEASED LEUKOPAKS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS) 153 TABLE 72 IMMUNE CELL TYPES AND TARGETED DISEASES 154 TABLE 73 ISOLATED PBMCS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 74 ISOLATED PBMCS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS) 156 TABLE 75 LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 159 TABLE 76 LEUKOPAKS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 77 LEUKOPAKS MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 78 LEUKOPAKS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 79 LEUKOPAKS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 80 LEUKOPAKS MARKET FOR PANCREATIC CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 81 LEUKOPAKS MARKET FOR HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 82 LEUKOPAKS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 83 LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 171 TABLE 84 LEUKOPAKS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 85 LEUKOPAKS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 86 LEUKOPAKS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 87 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 178 TABLE 88 LEUKOPAKS MARKET, BY REGION, 2024–2031 (USD MILLION) 178 TABLE 89 MAJOR LEUKAPHERESIS MARKET PLAYERS IN NORTH AMERICA 180 TABLE 90 NORTH AMERICA: LEUKAPHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 91 NORTH AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 182 TABLE 92 NORTH AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 182 TABLE 93 NORTH AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 182 TABLE 94 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 183 TABLE 95 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 183 TABLE 96 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 184 TABLE 97 US: KEY MACROINDICATORS 185 TABLE 98 US: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 186 TABLE 99 US: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 186 TABLE 100 US: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 186 TABLE 101 US: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 102 US: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 187 TABLE 103 US: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 188 TABLE 104 CANADA: KEY MACROINDICATORS 188 TABLE 105 CANADA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 189 TABLE 106 CANADA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 189 TABLE 107 CANADA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 189 TABLE 108 CANADA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 109 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 190 TABLE 110 CANADA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 191 TABLE 111 EUROPE: LEUKOPAKS MARKET, BY LEUKOPAK TYPE, 2024–2031 (MILLION UNIT BAGS) 192 TABLE 112 EUROPE: LEUKAPHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 113 EUROPE: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 193 TABLE 114 EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 193 TABLE 115 EUROPE: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 194 TABLE 116 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 117 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 195 TABLE 118 EUROPE: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 195 TABLE 119 GERMANY: KEY MACROINDICATORS 197 TABLE 120 GERMANY: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 197 TABLE 121 GERMANY: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 197 TABLE 122 GERMANY: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 198 TABLE 123 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 124 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 199 TABLE 125 GERMANY: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 199 TABLE 126 UK: KEY MACROINDICATORS 200 TABLE 127 UK: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 200 TABLE 128 UK: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 200 TABLE 129 UK: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 201 TABLE 130 UK: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 131 UK: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 202 TABLE 132 UK: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 202 TABLE 133 FRANCE: KEY MACROINDICATORS 203 TABLE 134 SPAIN: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 203 TABLE 135 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 136 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 204 TABLE 137 SPAIN: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 205 TABLE 138 ITALY: KEY MACROINDICATORS 205 TABLE 139 ITALY: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 206 TABLE 140 ITALY: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 206 TABLE 141 ITALY: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 206 TABLE 142 ITALY: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 143 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 207 TABLE 144 ITALY: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 208 TABLE 145 SPAIN: KEY MACROINDICATORS 208 TABLE 146 NETHERLANDS: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 210 TABLE 147 NETHERLANDS: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 210 TABLE 148 NETHERLANDS: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 149 NETHERLANDS: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 150 NETHERLANDS: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 211 TABLE 151 NETHERLANDS: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 212 TABLE 152 POLAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 212 TABLE 153 POLAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 213 TABLE 154 POLAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 213 TABLE 155 POLAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 156 POLAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 214 TABLE 157 POLAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 214 TABLE 158 SWITZERLAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 215 TABLE 159 SWITZERLAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 215 TABLE 160 SWITZERLAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 216 TABLE 161 SWITZERLAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 162 SWITZERLAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 217 TABLE 163 SWITZERLAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 217 TABLE 164 REST OF EUROPE: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 218 TABLE 165 REST OF EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218 TABLE 166 REST OF EUROPE: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 218 TABLE 167 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 168 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 219 TABLE 169 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 220 TABLE 170 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 171 ASIA PACIFIC: LEUKOPAK PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 172 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 223 TABLE 173 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 223 TABLE 174 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 224 TABLE 175 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 176 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 177 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 225 TABLE 178 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 226 TABLE 179 ASIA PACIFIC: LEUKOPAKS MARKET, BY LEUKOPAK TYPE, 2024–2031 (MILLION UNIT BAGS) 226 TABLE 180 CHINA: KEY MACROINDICATORS 228 TABLE 181 CHINA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 228 TABLE 182 CHINA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 228 TABLE 183 CHINA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 229 TABLE 184 CHINA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 185 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 230 TABLE 186 CHINA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 230 TABLE 187 JAPAN: KEY MACROINDICATORS 231 TABLE 188 JAPAN: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 232 TABLE 189 JAPAN: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 232 TABLE 190 JAPAN: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 232 TABLE 191 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 192 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 233 TABLE 193 JAPAN: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 234 TABLE 194 INDIA: KEY MACROINDICATORS 235 TABLE 195 INDIA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 235 TABLE 196 INDIA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 236 TABLE 197 INDIA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 236 TABLE 198 INDIA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 199 INDIA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 237 TABLE 200 INDIA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 237 TABLE 201 AUSTRALIA: KEY MACROINDICATORS 239 TABLE 202 AUSTRALIA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 239 TABLE 203 AUSTRALIA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 239 TABLE 204 AUSTRALIA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 240 TABLE 205 AUSTRALIA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 206 AUSTRALIA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 241 TABLE 207 AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 241 TABLE 208 SOUTH KOREA: KEY MACROINDICATORS 242 TABLE 209 SOUTH KOREA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 243 TABLE 210 SOUTH KOREA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 243 TABLE 211 SOUTH KOREA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 243 TABLE 212 SOUTH KOREA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 213 SOUTH KOREA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 244 TABLE 214 SOUTH KOREA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 244 TABLE 215 NEW ZEALAND: KEY MACROINDICATORS 245 TABLE 216 NEW ZEALAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 246 TABLE 217 NEW ZEALAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246 TABLE 218 NEW ZEALAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 219 NEW ZEALAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 220 NEW ZEALAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 247 TABLE 221 NEW ZEALAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 248 TABLE 222 THAILAND: KEY MACROINDICATORS 249 TABLE 223 THAILAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 249 TABLE 224 THAILAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 249 TABLE 225 THAILAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 250 TABLE 226 THAILAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 227 THAILAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 251 TABLE 228 THAILAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 251 TABLE 229 ROAPAC: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 252 TABLE 230 ROAPAC: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 252 TABLE 231 ROAPAC: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 253 TABLE 232 ROAPAC: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 233 ROAPAC: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 254 TABLE 234 ROAPAC: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 254 TABLE 235 LATIN AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 255 TABLE 236 LATIN AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 255 TABLE 237 LATIN AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 256 TABLE 238 LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 239 LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 257 TABLE 240 LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 241 BRAZIL: KEY MACROINDICATORS 259 TABLE 242 BRAZIL: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 259 TABLE 243 BRAZIL: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 260 TABLE 244 BRAZIL: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 260 TABLE 245 BRAZIL: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 246 BRAZIL: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 261 TABLE 247 BRAZIL: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 261 TABLE 248 MEXICO: KEY MACROINDICATORS 262 TABLE 249 MEXICO: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 262 TABLE 250 MEXICO: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263 TABLE 251 MEXICO: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 263 TABLE 252 MEXICO: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 253 MEXICO: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 264 TABLE 254 MEXICO: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 264 TABLE 255 REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 265 TABLE 256 REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 265 TABLE 257 REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 266 TABLE 258 REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 259 REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 267 TABLE 260 REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 267 TABLE 261 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 269 TABLE 262 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 269 TABLE 263 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 269 TABLE 264 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 265 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 270 TABLE 266 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 271 TABLE 267 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY LEUKOPAK TYPE, 2024–2031 (MILLION UNIT BAGS) 271 TABLE 268 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 273 TABLE 269 KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 273 TABLE 270 KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 274 TABLE 271 KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 274 TABLE 272 KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 273 KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 275 TABLE 274 KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 275 TABLE 275 UNITED ARAB EMIRATES (UAE): KEY MACROINDICATORS 276 TABLE 276 UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 276 TABLE 277 UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277 TABLE 278 UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 277 TABLE 279 UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 280 UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 278 TABLE 281 UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 278 TABLE 282 OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 279 TABLE 283 OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 279 TABLE 284 OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 280 TABLE 285 OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 286 OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 281 TABLE 287 OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 281 TABLE 288 REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 282 TABLE 289 REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 282 TABLE 290 REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 283 TABLE 291 REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 292 REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 284 TABLE 293 REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 284 TABLE 294 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN LEUKAPHERESIS MARKET, JANUARY 2023–MARCH 2026 286 TABLE 295 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN LEUKOPAKS MARKET, JANUARY 2023–MARCH 2026 287 TABLE 296 LEUKAPHERESIS MARKET: DEGREE OF COMPETITION 290 TABLE 297 LEUKOPAKS MARKET: DEGREE OF COMPETITION 292 TABLE 298 LEUKOPAKS MARKET: REGION FOOTPRINT 294 TABLE 299 LEUKOPAKS MARKET: BY PRODUCT TYPE FOOTPRINT 295 TABLE 300 LEUKOPAKS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 297 TABLE 301 LEUKOPAKS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 298 TABLE 302 LEUKAPHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 303 TABLE 303 LEUKAPHERESIS MARKET: DEALS, JANUARY 2023–MARCH 2026 304 TABLE 304 LEUKAPHERESIS MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026 305 TABLE 305 LEUKOPAKS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 305 TABLE 306 LEUKOPAKS MARKET: DEALS, JANUARY 2023–MARCH 2026 307 TABLE 307 LEUKOPAKS MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026 309 TABLE 308 TERUMO CORPORATION: COMPANY OVERVIEW 311 TABLE 309 TERUMO CORPORATION: PRODUCTS OFFERED 312 TABLE 310 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 314 TABLE 311 TERUMO CORPORATION: DEALS, JANUARY 2023–MARCH 2026 314 TABLE 312 TERUMO CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026 315 TABLE 313 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 317 TABLE 314 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED 318 TABLE 315 FRESENIUS SE & CO. KGAA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 319 TABLE 316 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2023–MARCH 2026 320 TABLE 317 FRESENIUS SE & CO. KGAA: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 320 TABLE 318 HAEMONETICS CORPORATION: COMPANY OVERVIEW 322 TABLE 319 HAEMONETICS CORPORATION: PRODUCTS OFFERED 323 TABLE 320 HAEMONETICS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 326 TABLE 321 HAEMONETICS CORPORATION: DEALS, JANUARY 2023–MARCH 2026 326 TABLE 322 NIKKISO CO., LTD.: COMPANY OVERVIEW 328 TABLE 323 NIKKISO CO., LTD.: PRODUCTS OFFERED 329 TABLE 324 NIKKISO CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 330 TABLE 325 SUMITOMO BAKELITE CO., LTD.: COMPANY OVERVIEW 331 TABLE 326 SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED 332 TABLE 327 DANAHER CORPORATION: COMPANY OVERVIEW 334 TABLE 328 DANAHER CORPORATION: PRODUCTS OFFERED 335 TABLE 329 OTSUKA HOLDINGS CO., LTD.: COMPANY OVERVIEW 336 TABLE 330 OTSUKA HOLDINGS CO., LTD: PRODUCTS OFFERED 337 TABLE 331 ASAHI KASEI MEDICAL CO., LTD.: COMPANY OVERVIEW 338 TABLE 332 ASAHI KASEI MEDICAL CO., LTD.: PRODUCTS OFFERED 338 TABLE 333 ASAHI KASEI MEDICAL CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 339 TABLE 334 MACOPHARMA SA: COMPANY OVERVIEW 340 TABLE 335 MACOPHARMA SA: PRODUCTS OFFERED 340 TABLE 336 MEDICA SPA: COMPANY OVERVIEW 342 TABLE 337 MEDICA SPA: PRODUCTS OFFERED 342 TABLE 338 POLYMED: COMPANY OVERVIEW 343 TABLE 339 PURIBLOOD MEDICAL: COMPANY OVERVIEW 344 TABLE 340 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 345 TABLE 341 SAFETRAN BIOMEDICAL INC.: COMPANY OVERVIEW 346 TABLE 342 MITRA INDUSTRIES PRIVATE LIMITED: COMPANY OVERVIEW 347 TABLE 343 LONZA: COMPANY OVERVIEW 348 TABLE 344 LONZA: PRODUCTS OFFERED 349 TABLE 345 LONZA: DEALS, JANUARY 2023–MARCH 2026 351 TABLE 346 GRIFOLS: COMPANY OVERVIEW 352 TABLE 347 GRIFOLS: PRODUCTS OFFERED 353 TABLE 348 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW 355 TABLE 349 CHARLES RIVER LABORATORIES: PRODUCTS OFFERED 356 TABLE 350 CHARLES RIVER LABORATORIES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 358 TABLE 351 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023–MARCH 2026 358 TABLE 352 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2023–MARCH 2026 359 TABLE 353 CELLEX CELL PROFESSIONALS: COMPANY OVERVIEW 360 TABLE 354 CELLEX CELL PROFESSIONALS: PRODUCTS OFFERED 361 TABLE 355 CELLEX CELL PROFESSIONALS: DEALS, JANUARY 2023–MARCH 2026 361 TABLE 356 CELLEX CELLS PROFESSIONALS: EXPANSIONS, JANUARY 2023–MARCH 2026 362 TABLE 357 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW 363 TABLE 358 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED 363 TABLE 359 BIOIVT: COMPANY OVERVIEW 365 TABLE 360 BIOIVT: PRODUCTS OFFERED 365 TABLE 361 BIOIVT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 367 TABLE 362 BIOIVT: DEALS, JANUARY 2023–MARCH 2026 367 TABLE 363 BIOIVT: EXPANSIONS, JANUARY 2023–MARCH 2026 367 TABLE 364 DISCOVERY LIFE SCIENCES: COMPANY OVERVIEW 368 TABLE 365 DISCOVERY LIFE SCIENCES: PRODUCTS OFFERED 368 TABLE 366 DISCOVERY LIFE SCIENCES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 370 TABLE 367 DISCOVERY LIFE SCIENCES: DEALS, JANUARY 2023–MARCH 2026 370 TABLE 368 DISCOVERY LIFE SCIENCES: EXPANSIONS, JANUARY 2023–MARCH 2026 370 TABLE 369 MILTENYI BIOTEC: COMPANY OVERVIEW 371 TABLE 370 MILTENYI BIOTEC: PRODUCTS OFFERED 372 TABLE 371 STEMVIVO INC.: COMPANY OVERVIEW 373 TABLE 372 STEMVIVO INC.: PRODUCTS OFFERED 374 TABLE 373 CGT GLOBAL: COMPANY OVERVIEW 375 TABLE 374 CGT GLOBAL: PRODUCTS OFFERED 375 TABLE 375 CGT GLOBAL: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 377 TABLE 376 SANGUINE BIOSCIENCES: COMPANY OVERVIEW 378 TABLE 377 SANGUINE BIOSCIENCES: PRODUCTS OFFERED 378 TABLE 378 SANGUINE BIOSCIENCES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 379 TABLE 379 BIOMEX GMBH: COMPANY OVERVIEW 380 TABLE 380 ACCEGEN: COMPANY OVERVIEW 381 TABLE 381 EXCELLOS: COMPANY OVERVIEW 382 TABLE 382 FIRST CHOICE BIO INC.: COMPANY OVERVIEW 383 TABLE 383 ORGANA BIO: COMPANY OVERVIEW 384 TABLE 384 HUMAN CELLS BIO: COMPANY OVERVIEW 384 TABLE 385 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON LEUKAPHERESIS MARKET 395 TABLE 386 RISK ASSESSMENT: LEUKAPHERESIS MARKET 398 FIGURE 1 LEUKAPHERESIS MARKET: SEGMENTATION & REGIONAL SCOPE 33 FIGURE 2 LEUKAPHERESIS MARKET: YEARS CONSIDERED 35 FIGURE 3 MARKET SCENARIO 38 FIGURE 4 LEUKAPHERESIS MARKET, 2026–2031 39 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKOPAKS MARKET, 2024–2026 39 FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKAPHERESIS MARKET, 2024–2026 40 FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF LEUKAPHERESIS MARKET 41 FIGURE 8 HIGH-GROWTH SEGMENTS IN LEUKOPAKS MARKET, 2026–2031 42 FIGURE 9 HIGH-GROWTH SEGMENTS IN LEUKAPHERESIS MARKET, 2026–2031 42 FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LEUKAPHERESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 43 FIGURE 11 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LEUKOPAKS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 44 FIGURE 12 GROWING INCIDENCE OF CANCER TO DRIVE MARKET 45 FIGURE 13 BLOOD COMPONENT PROVIDERS AND BLOOD CENTERS SEGMENT AND JAPAN ACCOUNTED FOR LARGEST MARKET SHARES IN 2025 46 FIGURE 14 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD 47 FIGURE 15 GROWING PREVALENCE OF LEUKEMIA AND ADOPTION OF CAR T-CELL THERAPY TO DRIVE MARKET 48 FIGURE 16 MOBILIZED LEUKOPAKS SEGMENT AND CHINA ACCOUNTED FOR LARGEST MARKET SHARES IN 2025 49 FIGURE 17 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD 50 FIGURE 18 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51 FIGURE 19 ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020 VS. 2040) 53 FIGURE 20 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020 VS. 2040) 53 FIGURE 21 LEUKAPHERESIS MARKET: PORTER'S FIVE FORCES ANALYSIS 66 FIGURE 22 LEUKAPHERESIS MARKET: SUPPLY CHAIN ANALYSIS 70 FIGURE 23 LEUKAPHERESIS MARKET: VALUE CHAIN ANALYSIS 71 FIGURE 24 LEUKOPAKS MARKET: VALUE CHAIN ANALYSIS 72 FIGURE 25 LEUKAPHERESIS MARKET ECOSYSTEM 74 FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS IN LEUKAPHERESIS MARKET 83 FIGURE 27 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN LEUKOPAKS MARKET 84 FIGURE 28 INVESTMENT & FUNDING SCENARIO FOR LEUKAPHERESIS MARKET PLAYERS 85 FIGURE 29 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR LEUKAPHERESIS PATENTS (JANUARY 2015–MARCH 2026) 98 FIGURE 30 LEUKAPHERESIS MARKET: AI USE CASES 102 FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LEUKOPAKS 110 FIGURE 32 KEY BUYING CRITERIA FOR LEUKOPAKS, BY TYPE 111 FIGURE 33 NORTH AMERICA: LEUKAPHERESIS MARKET SNAPSHOT 181 FIGURE 34 NORTH AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS) 184 FIGURE 35 EUROPE VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS) 196 FIGURE 36 ASIA PACIFIC: LEUKAPHERESIS MARKET SNAPSHOT 222 FIGURE 37 ASIA PACIFIC VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS) 226 FIGURE 38 LATIN AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS) 258 FIGURE 39 MIDDLE EAST & AFRICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS) 272 FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN LEUKAPHERESIS MARKET, 2023–2025 288 FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN LEUKOPAKS MARKET, 2023–2025 289 FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LEUKAPHERESIS MARKET, 2025 290 FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LEUKOPAKS MARKET, 2025 291 FIGURE 44 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 293 FIGURE 45 LEUKOPAKS MARKET: COMPANY FOOTPRINT 294 FIGURE 46 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 296 FIGURE 47 EV/EBITDA OF KEY VENDORS FOR LEUKAPHERESIS 298 FIGURE 48 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR LEUKAPHERESIS 299 FIGURE 49 EV/EBITDA OF KEY VENDORS FOR LEUKOPAKS 299 FIGURE 50 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR LEUKOPAKS 300 FIGURE 51 LEUKOPAKS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 301 FIGURE 52 LEUKAPHERESIS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 302 FIGURE 53 TERUMO CORPORATION: COMPANY SNAPSHOT (2025) 312 FIGURE 54 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2025) 318 FIGURE 55 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2025) 323 FIGURE 56 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2025) 329 FIGURE 57 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2025) 332 FIGURE 58 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 335 FIGURE 59 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2025) 337 FIGURE 60 LONZA: COMPANY SNAPSHOT (2025) 349 FIGURE 61 GRIFOLS: COMPANY SNAPSHOT (2025) 353 FIGURE 62 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2025) 356 FIGURE 63 LEUKAPHERESIS MARKET: RESEARCH DESIGN 386 FIGURE 64 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET) 389 FIGURE 65 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS MARKET) 389 FIGURE 66 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION (LEUKAPHERESIS MARKET) 390 FIGURE 67 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET) 390 FIGURE 68 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION (LEUKOPAKS MARKET) 391 FIGURE 69 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 392 FIGURE 70 REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2025) 392 FIGURE 71 DEMAND-SIDE APPROACH: LEUKAPHERESIS MARKET (2025) 393 FIGURE 72 LEUKAPHERESIS MARKET: CAGR PROJECTIONS (2026–2031) 394 FIGURE 73 TOP-DOWN APPROACH 395 FIGURE 74 DATA TRIANGULATION METHODOLOGY 396

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們